Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors.

Choueiri, T K; Je, Y; Sonpavde, G; Richards, C J; Galsky, M D; Nguyen, P L; Schutz, F; Heng, D Y; Kaymakcalan, M D

Choueiri, T K; Je, Y; Sonpavde, G; Richards, C J; Galsky, M D; Nguyen, P L; Schutz, F; Heng, D Y; Kaymakcalan, M D.

Affiliation

Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Ann Oncol ; 24(8): 2092-7, 2013 Aug.

Article in En | MEDLINE | ID: mdl-23658373

Subject(s)

Sirolimus/analogs & derivatives; TOR Serine-Threonine Kinases/antagonists & inhibitors; Antineoplastic Agents/adverse effects; Antineoplastic Agents/therapeutic use; Carcinoma, Renal Cell/drug therapy; Carcinoma, Renal Cell/mortality; Everolimus; Humans; Immunosuppressive Agents/adverse effects; Immunosuppressive Agents/therapeutic use; Kidney Neoplasms/drug therapy; Kidney Neoplasms/mortality; Protein Kinase Inhibitors/adverse effects; Protein Kinase Inhibitors/therapeutic use; Risk; Sirolimus/adverse effects; Sirolimus/therapeutic use

Key words

cancer; fatal adverse events; mTOR inhibitors; meta-analysis; renal cell carcinoma

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sirolimus / TOR Serine-Threonine Kinases Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Risk_factors_studies / Systematic_reviews Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2013 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google